Discovery Analysis Demonstrates Transformative Sensitivity of 95% with Specificity of 98% for the Detection of Pancreatic Cancer in Blood Samples Mainz Biomed Enters into Exclusive Licensing Agreement for the Portfolio of mRNA Biomarkers, with Continued Development of Machine Learning AI-Based Algorithm Based on Liquid Biosciences EMERGE Platform BERKELEY, Calif. and MAINZ, Germany, March 13, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
BERKELEY, Calif. and MAINZ, Germany, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
eAArly DETECT 2 feasibility study designed to validate earlier results on advanced adenomas over a large population of average risk patients Multi-center study expected to complete enrollment in the second half and reporting in the Fourth Quarter of 2025 BERKELEY, Calif. and MAINZ, Germany, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the launch of eAArly DETECT 2, a U.S. feasibility study to evaluate the Company's next generation colorectal cancer (CRC) test, integrating its proprietary mRNA biomarkers, AI developed algorithm and FIT test, over a population of approximately 2,000 patients, all of average risk, to validate the industry leading results of previous feasibility studies, which included average risk and identified risk patients.
BERKELEY, Calif. and MAINZ, Germany, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
BERKELEY, Calif. and MAINZ, Germany, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed N.V. MYNZ announced a 1-for-40 reverse stock split, effective Dec. 3.
BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Revenue increases 4% year over year while loss from operations decreases by 32% Pooled Results of ColoFuture and eAArly DETECT studies published at ASCO showing groundbreaking performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia Company highlights its path to success for 2025 BERKELEY, Calif. and MAINZ, Germany, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
BERKELEY, Calif. and MAINZ, Germany, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
BERKELEY, Calif. and MAINZ, Germany, Sept.